OGT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4544769	1.00	15/20
SCHEMBL4544682	1.00	14/20
SCHEMBL4544693	1.00	14/20
SCHEMBL4544718	1.00	14/20
SCHEMBL4544765	1.00	14/20
SCHEMBL4544678	1.00	13/20
SCHEMBL4544662	1.00	12/20
SCHEMBL4544723	1.00	12/20
SCHEMBL4544745	1.00	12/20
SCHEMBL4544665	1.00	10/20
SCHEMBL4544697	1.00	10/20
SCHEMBL4544777	1.00	10/20
SCHEMBL2633965	0.51	10/20
SCHEMBL4544773	1.00	9/20
SCHEMBL4547301	1.00	9/20
SCHEMBL4544776	0.88	9/20
SCHEMBL4544735	0.74	9/20
SCHEMBL4547382	0.54	9/20
SCHEMBL4544775	1.00	8/20
SCHEMBL4544668	0.66	8/20

Clinical trials — most relevant to OGT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling	PHASE4	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery	PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Cross-Sectional and Longitudinal Studies of Pre-Diabetes in the Pima Indians	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Cord Blood Preptin Levels in Infants	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Coronary Artery Plaque Burden in Asymptomatic Danish Men Aged 65-75 Years and the Relation to Glycemic Status.	nan	COMPLETED
Disease Prevention in Clinical Practice Base on Patient Specific Physiology	nan	ENROLLING_BY_INVITATION
Genetic Physiopathology and Evolution of Type 2 Diabetes	nan	COMPLETED
Assessment of HGI (Hemoglobin Glycation Index) Variability Over Time in Patients Living With Diabetes Using Continuous Glucose Monitoring ( GAP OUEST )	nan	ACTIVE_NOT_RECRUITING
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease	nan	COMPLETED
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a OGT binder may also engage these)

Protein	Name	Similarity
Q27HV0	—	1.000	Q27HV0 →
Q8CGY8	—	1.000	Q8CGY8 →
P56558	—	1.000	P56558 →
P81436	—	1.000	P81436 →
CDC16	Cell division cycle protein 16 homolog	0.950	landscape →
P79101	—	0.947	P79101 →
Q6IQT4	—	0.947	Q6IQT4 →
Q9UKF6	—	0.946	Q9UKF6 →
P61202	—	0.946	P61202 →
Q9NQX3	—	0.945	Q9NQX3 →
Q8R349	—	0.945	Q8R349 →
Q9PW38	—	0.944	Q9PW38 →
Q6IR75	—	0.944	Q6IR75 →
Q8C6G8	—	0.944	Q8C6G8 →
DHX9	ATP-dependent RNA helicase A	0.944	landscape →
Q9UL63	—	0.944	Q9UL63 →
COPS2	COP9 signalosome complex subunit 2	0.944	landscape →
Q9QXK7	—	0.943	Q9QXK7 →
Q8BUV3	—	0.943	Q8BUV3 →
O89050	—	0.943	O89050 →
Q5R874	—	0.942	Q5R874 →
P61203	—	0.941	P61203 →
Q99PV3	—	0.941	Q99PV3 →
WDR26	WD repeat-containing protein 26	0.940	landscape →
Q03555	—	0.940	Q03555 →
Q28D01	—	0.940	Q28D01 →
Q6GR10	—	0.939	Q6GR10 →
Q4R9A8	—	0.938	Q4R9A8 →
Q91854	—	0.938	Q91854 →
Q5RB35	—	0.937	Q5RB35 →